| Date Filed | Type | Description |
| 08/10/2023 |
4
| Goff Brian (CEO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 10,178 shares
@ $25.48, valued at
$259.3k
Exercised 22,691 restricted stock units
@ $0 |
|
| 06/30/2023 |
4
| Goff Brian (CEO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.|
Txns:
| Sold 11,449 shares
@ $28.36, valued at
$324.7k
Exercised 25,528 options to buy
@ $0 |
|
| 08/09/2022 |
3/A
| Form 3/A - Initial statement of beneficial ownership of securities: [Amend] |
| 08/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/09/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/23/2021 |
4
| Goff Brian (EVP & Chief Commercial Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 150,832 shares
@ $0
Disposed/sold 21,750 options to buy
@ $100.14, valued at
$2.2M
|
|
| 07/16/2021 |
4
| Goff Brian (EVP & Chief Commercial Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Granted 30,643 shares
@ $0
Granted 29,501 shares
@ $0 |
|
| 06/09/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/18/2020 |
4
| Goff Brian (EVP & Chief Commercial Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Granted 40,677 shares
@ $0
Paid exercise price by delivering 18,134 shares
@ $157.96, valued at
$2.9M
Paid exercise price by delivering 3,261 shares
@ $157.96, valued at
$515.1k
|
|
| 06/09/2020 |
4
| Goff Brian (EVP & Chief Commercial Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,642 shares
@ $114.61, valued at
$188.2k
|
|
| 03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/10/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/11/2019 |
4
| Goff Brian (EVP & Chief Commercial Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,643 shares
@ $118.61, valued at
$194.9k
|
|
| 03/05/2019 |
4
| Goff Brian (EVP & Chief Commercial Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Granted 9,428 shares
@ $0 |
|
| 03/04/2019 |
4
| Goff Brian (EVP & Chief Commercial Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 670 shares
@ $132.93, valued at
$89.1k
|
|
| 02/11/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/12/2018 |
4
| Goff Brian (EVP & Chief Commercial Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS INC|
Txns:
| Sold 1,645 shares
@ $118.53, valued at
$195k
|
|
| 03/02/2018 |
4
| Goff Brian (EVP & Chief Commercial Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS INC|
Txns:
| Granted 8,940 shares
@ $0 |
|
| 02/08/2018 |
4
| Goff Brian (EVP & Chief Commercial Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS INC|
Txns:
| Granted 15,894 shares
@ $0
Sold 1,651 shares
@ $116.31, valued at
$192k
|
|
| 06/09/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 06/09/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
| 06/07/2016 |
4
| Goff Brian (EVP and President, Hematology) has filed a Form 4 on Baxalta Inc|
Txns:
| Granted 2,881 shares
@ $0
Disposed/sold 70,047 shares
@ $0
Disposed/sold 37,000 options to buy
@ $23.15, valued at
$856.6k
Disposed/sold 25,773 options to buy
@ $32.42, valued at
$835.6k
Disposed/sold 31,376 options to buy
@ $31.86, valued at
$999.6k
Disposed/sold 88,168 options to buy
@ $32.04, valued at
$2.8M
Disposed/sold 35,170 options to buy
@ $31.5, valued at
$1.1M
Disposed/sold 265,221 options to buy
@ $31.5, valued at
$8.4M
|
|
| 03/08/2016 |
4
| Goff Brian (EVP and President, Hematology) has filed a Form 4 on Baxalta Inc|
Txns:
| Paid exercise price by delivering 267 shares
@ $39.74, valued at
$10.6k
|
|
| 03/07/2016 |
4
| Goff Brian (EVP and President, Hematology) has filed a Form 4 on Baxalta Inc|
Txns:
| Granted 35,605 shares
@ $0
Paid exercise price by delivering 1,338 shares
@ $39.3, valued at
$52.6k
Paid exercise price by delivering 303 shares
@ $39.47, valued at
$12k
|
|
| 02/17/2016 |
4
| Goff Brian (EVP and President, Hematology) has filed a Form 4 on Baxalta Inc|
Txns:
| Granted 552 shares
@ $0
Paid exercise price by delivering 533 shares
@ $39, valued at
$20.8k
Granted 508 shares
@ $0 |
|
| 08/13/2015 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/06/2015 |
4
| Goff Brian (EVP and President, Hematology) has filed a Form 4 on Baxalta Inc|
Txns:
| Acquired 4,154 shares
@ $0
Acquired 28,154 shares
@ $0
Acquired 37,000 options to buy
@ $23.15, valued at
$856.6k
Acquired 25,773 options to buy
@ $32.42, valued at
$835.6k
Acquired 31,376 options to buy
@ $31.86, valued at
$999.6k
Acquired 88,168 options to buy
@ $32.04, valued at
$2.8M
Granted 35,170 options to buy
@ $31.5, valued at
$1.1M
Granted 265,221 options to buy
@ $31.5, valued at
$8.4M
|
|
| 04/05/2012 |
3
| Goff Brian (Director) has filed a Form 3 on IDENIX PHARMACEUTICALS INC |